Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Contineum Therapeutics (CTNM) Other financing activities (2023 - 2024)

Contineum Therapeutics' Other financing activities history spans 2 years, with the latest figure at $140000.0 for Q1 2024.

Quarterly Other financing activities rose 2700.0% to $140000.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $157000.0 through Mar 2024, changed N/A year-over-year, with the annual reading at $22000.0 for FY2023, N/A changed from the prior year.
Other financing activities came in at $140000.0 for Q1 2024, up from $1000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $140000.0 in Q1 2024 to a low of $1000.0 in Q4 2023.